Nirsevimab Prophylaxis and Respiratory Syncytial Virus Hospitalizations Among Infants
In this multicenter cohort study, nirsevimab prophylaxis was associated with substantially lower RSV hospitalization risk and reduced in-hospital RSV severity, supporting its implementation as a public health strategy. However, the persistent risk associated with prematurity and household RSV exposure suggests a need for supplemental approaches to optimize RSV prevention in high-risk infants.
Authors
- Silvia Bloise (ORCID: https://orcid.org/0000-0002-2853-8318)
- Federico Marchetti (ORCID: https://orcid.org/0000-0002-1257-7312)
- Gina Ancora (ORCID: https://orcid.org/0000-0002-2570-2020)
- Enrico Valletta (ORCID: https://orcid.org/0000-0003-4149-4804)
- Melodie O. Aricò (ORCID: https://orcid.org/0000-0003-2072-3559)
- Enrico Cocchi (ORCID: https://orcid.org/0000-0002-7532-956X)
- Beatrice Scarpellini
- Francesco Accomando (ORCID: https://orcid.org/0000-0002-3205-106X)
- Marcello Stella
- Gianluca Vergine
- Sara Zannoni
- Aurora Lorefice
- Benedetta Pellegrini
- Francesco Saverio Morlupo
Institutions
- University of Ferrara (IT)
- Azienda Unità Sanitaria Locale Della Romagna (IT)
- Ospedale “M. Bufalini” di Cesena (IT)
- Precision for Medicine (United States) (US)
- Ospedale Infermi di Rimini (IT)
- Istituto Oncologico Romagnolo (IT)
- Columbia University (US)
- University of Bologna (IT)
Publication Details
- Journal
- JAMA Network Open
- Published
- 2025-11-20
- DOI
- https://doi.org/10.1001/jamanetworkopen.2025.44679
- Citations
- 4
- Primary Topic
- Respiratory viral infections research
- Type
- article
- Field-Weighted Citation Impact
- 5.42